Books and Book Chapters

    Systems Biology: Methods and Applications

    Titz, B.; Knorr, A.; Sewer, A.; Martin, F.; Ivanov, N. V.; Talikka, M.; Gonzalez-Suarez, I.; Peitsch, M. C.; Hoeng, J.

    Date published
    Jun 13, 2017
    DOI
    10.1016/B978-0-12-409547-2.12333-9
    ISBN
    978-0-12-803201-5
    Published in
    Comprehensive Medicinal Chemistry III
    Editors
    Chackalamannil, S.; Rotella, D.; Ward, S. E.
    Link to publication
    Topic
    Summary

    Traditional reductionist approaches play a crucial role in our understanding of biology and medicine, but they cannot explain the full complexity of biological phenomena and human disease. Systems biology combines recent high-throughput profiling technologies—such as transcriptomics, proteomics, and metabolomics—with computational modeling to capture, summarize, and understand this complexity. In this article, we provide a detailed overview of these experimental profiling technologies and computational modeling approaches. Several case studies illustrate how system approaches are already effectively used in toxicology assessment, drug development, diagnostics, and personalized medicine. Overall, this article provides the foundations to further integrate systems biology approaches into biomedical research.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.